1. Home
  2. TNXP vs EVGN Comparison

TNXP vs EVGN Comparison

Compare TNXP & EVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$13.90

Market Cap

172.7M

Sector

Health Care

ML Signal

HOLD

Logo Evogene Ltd

EVGN

Evogene Ltd

HOLD

Current Price

$0.78

Market Cap

6.7M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
EVGN
Founded
2007
1999
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Agricultural Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
172.7M
6.7M
IPO Year
2008
2013

Fundamental Metrics

Financial Performance
Metric
TNXP
EVGN
Price
$13.90
$0.78
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.50
AVG Volume (30 Days)
404.1K
164.2K
Earning Date
05-11-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
91.75
N/A
EPS
N/A
N/A
Revenue
$13,107,000.00
N/A
Revenue This Year
$558.11
N/A
Revenue Next Year
$38.29
$73.33
P/E Ratio
N/A
N/A
Revenue Growth
29.85
N/A
52 Week Low
$11.60
$0.72
52 Week High
$69.65
$2.42

Technical Indicators

Market Signals
Indicator
TNXP
EVGN
Relative Strength Index (RSI) 47.63 43.76
Support Level $13.32 N/A
Resistance Level $20.36 $1.23
Average True Range (ATR) 1.18 0.07
MACD -0.04 0.00
Stochastic Oscillator 42.56 25.52

Price Performance

Historical Comparison
TNXP
EVGN

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About EVGN Evogene Ltd

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.

Share on Social Networks: